RSI low/high Values: [ 25 - 75 ]
* StockInvest.us uses dynamically calculated RSI max/min levels to determine when stock is oversold or overbought based on historical behavior.
AI Analysis of CNTX
Powered by GPT-4o
Upgraded!
Stock Analysis
Risk Assessment
Trading Strategy

Context Therapeutics Inc. stock price down 2.72% on Wednesday
(Updated on Jul 03, 2024)

Sell candidate since Jul 01, 2024 Loss -1.10% PDF

The Context Therapeutics Inc. stock price fell by -2.72% on the last day (Wednesday, 3rd Jul 2024) from $1.84 to $1.79. During the last trading day the stock fluctuated 4.55% from a day low at $1.76 to a day high of $1.84. The price has been going up and down for this period, and there has been a -11.39% loss for the last 2 weeks. Volume fell on the last day along with the stock, which is actually a good sign as volume should follow the stock. On the last day, the trading volume fell by -77 thousand shares and in total, 38 thousand shares were bought and sold for approximately $68.78 thousand.

Given the current short-term trend, the stock is expected to rise 54.49% during the next 3 months and, with a 90% probability hold a price between $2.77 and $3.50 at the end of this 3-month period.

Ready to grow your portfolio? Here's your beginner's guide to opening a free brokerage account.

CNTX Signals & Forecast

There are few to no technical positive signals at the moment. The Context Therapeutics Inc. stock holds sell signals from both short and long-term Moving Averages giving a more negative forecast for the stock. Also, there is a general sell signal from the relation between the two signals where the long-term average is above the short-term average. On corrections up, there will be some resistance from the lines at $1.95 and $1.95. A break-up above any of these levels will issue buy signals. A sell signal was issued from a pivot top point on Tuesday, June 25, 2024, and so far it has fallen -18.26%. Further fall is indicated until a new bottom pivot has been found. Furthermore, there is currently a sell signal from the 3 month Moving Average Convergence Divergence (MACD). Volume fell along with the price during the last trading day which is technical positive. One should, however, note that this stock may have low liquidity in periods, which increases the general risk. The very low volume increases the risk and reduces the other technical signals issued.

Support, Risk & Stop-loss for Context Therapeutics Inc. stock

Context Therapeutics Inc. finds support from accumulated volume at $1.78 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.

This stock may move much during the day (volatility) and with periodic low trading volume this stock is considered to be "high risk". During the last day, the stock moved $0.0800 between high and low, or 4.55%. For the last week the stock has had daily average volatility of 6.54%.

Our recommended stop-loss: We hold a negative evaluation for this stock. No stop-loss is set.

Trading Expectations (CNTX) For The Upcoming Trading Day Of Friday 5th

For the upcoming trading day on Friday, 5th we expect Context Therapeutics Inc. to open at $1.80, and during the day (based on 14 day Average True Range), to move between $1.62 and $1.96, which gives a possible trading interval of +/-$0.168 (+/-9.41%) up or down from last closing price. If Context Therapeutics Inc. takes out the full calculated possible swing range there will be an estimated 18.83% move between the lowest and the highest trading price during the day.

Since the stock is closer to the support from accumulated volume at $1.78 (0.56%) than the resistance at $1.85 (3.35%), our systems sees the trading risk/reward intra-day as attractive and believe profit can be made before the stock reaches first resistance..

Is Context Therapeutics Inc. stock A Buy?

The Context Therapeutics Inc. stock holds several negative signals and despite the positive trend, we believe Context Therapeutics Inc. will perform weakly in the next couple of days or weeks. Therefore, we hold a negative evaluation of this stock.

Current score: -1.614 Sell Candidate Unchanged

Predicted Opening Price for Context Therapeutics Inc. of Friday, July 5, 2024

Fair opening price July 5, 2024 Current price
$1.80 ( 0.372%) $1.79

The predicted opening price is based on yesterday's movements between high, low, and closing price.

Trading levels for CNTX

Fibonacci Support & Resistance Levels

Level Price
R3 1.88 4.84%
R2 1.85 3.13%
R1 1.83 2.08%
Price 1.79
S1 1.77 -1.33%
S2 1.75 -2.39%
S3 1.72 -4.10%

Accumulated Volume Support & Resistance Levels

Level Price
R3 2.17 21.23%
R2 2.16 20.67%
R1 1.85 3.35%
Price 1.79
S1 1.78 -0.559%
S2 1.75 -2.23%
S3 1.72 -3.91%

FAQ

What is the symbol for Context Therapeutics Inc. Stock and on which exchange is it traded?
The symbol for Context Therapeutics Inc. is CNTX and it is traded on the NASDAQ (NASDAQ Stock Exchange).

Should I buy or sell Context Therapeutics Inc. Stock?
The Context Therapeutics Inc. stock holds several negative signals and despite the positive trend, we believe Context Therapeutics Inc. will perform weakly in the next couple of days or weeks. Therefore, we hold a negative evaluation of this stock.

How to buy Context Therapeutics Inc. Stock?
Context Therapeutics Inc. Stock can be purchased through just about any brokerage firm, including online brokerage services.
Click here for our free guide on how to buy Context Therapeutics Inc. Stock.

What's the current price of Context Therapeutics Inc. Stock?
As of the end of day on the Jul 03, 2024, the price of an Context Therapeutics Inc. (CNTX) share was $1.79.

What is the 52-week high and low for Context Therapeutics Inc. Stock?
The 52-week high for Context Therapeutics Inc. Stock is $2.23 and the 52-week low is $0.770.

What is the market capitalization of Context Therapeutics Inc. Stock?
As of the Jul 03, 2024, the market capitalization of Context Therapeutics Inc. is 134.247M.

When is the next earnings date for Context Therapeutics Inc.?
The upcoming earnings date for Context Therapeutics Inc. is Aug 14, 2024.
Click to get the best stock tips daily for free!

About Context Therapeutics Inc.

Context Therapeutics. Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of cancer for women in the United States. Its lead product candidate is onapristone extended release (ONA-XR), a potent and selective antagonist of the progesterone receptor that is linked to resistance for various classes of cancer therapeutics, such as anti-estrogen therapies across female hormone-dependent cancers. The company is also dev... CNTX Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT